$3.20
9.49% day before yesterday
Nasdaq, Nov 14, 03:30 pm CET
ISIN
US28658R1068
Symbol
ELYM
Sector
Industry

Eliem Therapeutics Inc Stock price

$3.01
-2.09 40.98% 1M
-4.98 62.33% 6M
+0.31 11.48% YTD
+0.50 19.92% 1Y
-14.98 83.27% 3Y
-12.89 81.07% 5Y
-12.89 81.07% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.19 5.79%
ISIN
US28658R1068
Symbol
ELYM
Sector
Industry

Key metrics

Market capitalization $202.34m
Enterprise Value $9.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.92
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.23m
Free Cash Flow (TTM) Free Cash Flow $-10.99m
Cash position $193.35m
EPS (TTM) EPS $-2.13
Short interest 2.38%
Show more

Is Eliem Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Eliem Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Eliem Therapeutics Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Eliem Therapeutics Inc:

Hold
100%

Financial data from Eliem Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
55% 55%
-
- Research and Development Expense 8.78 8.78
49% 49%
-
-21 -21
53% 53%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -21 -21
53% 53%
-
Net Profit -69 -69
76% 76%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eliem Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eliem Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio's management team and an external expert who will provide an update to the investment community on the Company's strategy and focus on developing therapeutics for immune-mediated diseases.
Neutral
GlobeNewsWire
about one month ago
Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases
Neutral
GlobeNewsWire
2 months ago
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
More Eliem Therapeutics Inc News

Company Profile

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Head office United States
CEO Aoife Brennan
Employees 9
Founded 2018
Website www.climbbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today